fluorouracil has been researched along with molybdenum in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brewer, GJ; Gartner, EM; Griffith, KA; Henja, GF; Merajver, SD; Pan, Q; Zalupski, MM | 1 |
| Brard, L; Kim, KK; Lange, TS; Moore, RG; Singh, RK | 1 |
| Chang, AC; Hayman, JA; Lee, JS; Merajver, SD; Orringer, MB; Pan, CC; Pickens, A; Schneider, BJ; Urba, SG | 1 |
2 trial(s) available for fluorouracil and molybdenum
| Article | Year |
|---|---|
A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chelating Agents; Colorectal Neoplasms; Copper; Cytokines; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Molybdenum; Neoplasm Metastasis; Pilot Projects | 2009 |
Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Molybdenum; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Postoperative Care; Preoperative Care; Prognosis; Remission Induction; Survival Rate | 2013 |
1 other study(ies) available for fluorouracil and molybdenum
| Article | Year |
|---|---|
Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Death; Cell Line, Tumor; Doxorubicin; Female; Fenretinide; Flow Cytometry; Fluorouracil; Humans; Mitomycin; Molybdenum; Ovarian Neoplasms; Reactive Oxygen Species | 2012 |